Using blood tests to screen high-risk patients for lung cancer
Feasibility Study of Lung Cancer Screening Using Cell-Free DNA Liquid Biopsy at Home in High-Risk Current and Former Smokers
NA · City of Hope Medical Center · NCT05384769
This study is testing if a blood test can help high-risk patients get screened for lung cancer more easily and encourage them to follow up with further testing if needed.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 108 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | City of Hope Medical Center (other) |
| Locations | 1 site (Duarte, California) |
| Trial ID | NCT05384769 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the feasibility of using cell-free DNA liquid biopsy as a screening method for lung cancer in high-risk patients. Participants will choose between two cohorts: one undergoing a blood sample collection with the option for a low dose CT scan if results are positive, and the other receiving a low dose CT scan with an optional blood test. The study aims to assess follow-through rates for screening and compare sociodemographic factors among participants. The goal is to determine if liquid biopsy can encourage more patients to pursue further screening for lung cancer.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50-80 with a significant smoking history and a referral for lung cancer screening.
Not a fit: Patients currently exhibiting symptoms of lung cancer or those who have had recent imaging studies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of lung cancer in high-risk patients, improving treatment outcomes.
How similar studies have performed: Other studies have explored liquid biopsy for cancer detection, showing promising results, but this specific approach in a community setting is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented written informed consent of the participant. * Age 50-80 years. * Smoking history of \>= 20 pack-years and if quit, quit within 15 years. * Received referral for counseling for lung cancer screening and would qualify for LDCT. * Health Insurance that will pay for a LDCT for lung cancer screening at either City of Hope Duarte, Newport Beach (Newport Diagnostic Imaging), or Lancaster (Renaissance Imaging/Antelope Valley Outpatient Imaging Center). * Willingness to provide blood sample. * English speaking. * Consent to undergo lung cancer screening with either liquid biopsy (LB) or LDCT. Exclusion Criteria: * Symptoms of lung cancer. * Chest CT scan or chest positron emission tomography (PET)/CT within 12 months. * Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer. * Unable to undergo LDCT at either City of Hope Duarte, Newport Beach, or Lancaster.
Where this trial is running
Duarte, California
- City of Hope Medical Center — Duarte, California, United States (RECRUITING)
Study contacts
- Principal investigator: Dan Raz, MD — City of Hope Medical Center
- Study coordinator: Dan Raz, MD
- Email: draz@coh.org
- Phone: 626-359-8111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Carcinoma